Abstract:BackgroundOptimal immunosupression is crucial for transplant success. In orthohepatic transplants, blood target levels of tacrolimus, when coadministred with corticoids and mycophenolic acid, are between 6 and 10 ng/mL during the first three months post-transplant. Notwithstanding, achieving tacrolimus concentrations into this range may be tough because of factors such as liver function status, age, sex, drug-drug interactions, etc. In this way, pharmacogenetic testing of CYP3A5 and CYP3A4 genes have demonstrated to be useful in tacrolimus dosing optimization. Nonetheless, there is no evidence enough for pharmacogenetic based adjusting in liver transplant, specially if receptor and graft's genotypes differ in these loci .The aim of the present study is to find out how the receptor and donor genotypes in CYP3A5 and CYP3A4 genes affect tacrolimus pharmacokinetics.MethodsGenotypic profiling of 108 receptor-donor's pairs biopsies gathered from patients who were underwent hepatic transplant from 2012 to 2019 were carried out using Taqman ® OpenArrayTM PGx Express 120 panel (ThermoFisherTM). We focused on CYP3A5 *3, *6 and *7; and CYP3A4 *1B, *3 and *22 alleles. Next to pharmacogenetic testing, each patient was classified as very poor, poor, intermediate, rapid or ultrarapid metabolizer according to their own genotype, graft's genotype or both of them. Patient's initial dose, at seven days after treatment start and after discharge of tacrolimus and their trough concentrations (C 0 ) were collected from their electronic health records.Tacrolimus levels were measured by affinity chrome-mediated immunoassay. C 0 was normalized by weight-adjusted dosage (C/D ratio); then, median C/D ratios between different metabolic profiles were compared through Kruskal-Wallis test.ResultsWhen patients were classified based on donor's genotype isolated or combined with receptor's genotype, lower C/D ratios were found as metabolizer ability increases (p=0.045 for donors and p=0.027 for combined genotypes, respectively). No statistically differences were found for C/D ratios at seven days and discharge, though that differences were almost significant for donor's genotypes (p=0.06 in both cases).ConclusionsThese results show that previous information about both patient's and specially donor's CYP genes genotype may improve initial immunosupression and avoid tacrolimus induced toxicity. Pharmacogenetics has been currently proposed as a guide for tacrolimus treatment of some solid organ transplants as kidney transplanted patients. Better understanding of how receptor and donor's CYP genotype affects its pharmacokinetics, along with liver's damage markers and other genetic polymorphisms will allow clinicians, in the era of personalized medicine, to improve immunosupressive management.

Assessing the Utility of a Genotype‐Guided Tacrolimus Equation in African American Kidney Transplant Recipients: A Single Institution Retrospective Study

Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data

Genotype-guided Model Significantly Improves Accuracy of Tacrolimus Initial Dosing after Liver Transplantation

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients

Effects of CYP3A4 and CYP3A5 Polymorphisms on Tacrolimus Pharmacokinetics in Chinese Adult Renal Transplant Recipients: a Population Pharmacokinetic Analysis.

Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients

Genotype‐Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation

Optimizing tacrolimus dosing in Hispanic renal transplant patients: insights from real-world data

Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.

Guiding the starting dose of the once-daily formulation of tacrolimus in " de novo" adult renal transplant patients: a population approach

Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus

Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients.

Effect of CYP3A5 Genotype on Concentration and Efficacy of Tacrolimus in Patients with Kidney Transplantation

B-222 Receptor-donor CYP3A5 and CYP3A4 genotype testing in liver transplant patients and its influence in tacrolimus blood levels: a retrospective study